Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Filings indexed 719 across all filing types
Latest filing 2023-12-19 Director's Dealing
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2023-12-19 English
4
Director's Dealing
2023-12-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 18, 2023. It announces that Akero Therapeutics has dosed the first patients in a Phase 3 clinical trial program for their drug efruxifermin. The content is primarily a press release about a clinical trial milestone and forward-looking statements, not a financial report or detailed earnings data. There are no financial statements or substantive financial data included. The document is an event announcement related to clinical development progress, which fits best under Regulatory Filings (RNS) as it does not match any other specific category such as earnings release, annual report, or management discussion. The document length is about 5990 characters, which is sufficient for a full report but the content is clearly an announcement rather than a financial or management report.
2023-12-18 English
4
Director's Dealing
2023-12-12 English
4
Director's Dealing
2023-12-12 English
4
Director's Dealing
2023-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.